Grant Award Details
- To identify lead compounds targeting the main protease of SARS-CoV2 as therapeutics for COVID-19
Grant Application Details
- Development of COVID-19 Antiviral Therapy Using Human iPSC-Derived Lung Organoids
To develop a new therapy for COVID-19 using human iPSC-derived lung organoids that targets SARS-CoV-2 protease known as the virus’ “Achilles Heel”
Our work, if successful, will bring a class of new drugs directly targeting viral enzyme and open the door for future COVID therapies.
Major Proposed Activities
- Complete synthesis and testing of new inhibitors
- Optimize and validate the new compounds activities in lung cells and organoids
- Rapidly expand the efficacy of SARS-CoV-2 inhibitors in a large panel of lung organoids from African-American, Latino, and Caucasian men and women.
- ensure that any newly emerging therapy will be applicable to all patients regardless of gender and race.
The emergence of novel coronavirus SARS-CoV-2 and its associated disease, COVID-19, has presented an urgent global public health crisis. In California, more than 700,000 individuals have been infected leading ~13,000 deaths. Further, Californians are grappling with the economic impact due to job loss and business shutdowns. Finding a treatment for COVID-19 would have a huge impact on saving lives, preventing new infections, and helping people to return to normal activities of life.
- J Med Chem (2021) Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors. (PubMed: 34570513)